Last updated: February 20, 2026
What is the scope of patent GB201522309?
Patent GB201522309, filed in the United Kingdom, covers a specific formulation and method related to a pharmaceutical compound. The patent explicitly claims a novel pharmaceutical composition comprising a particular active ingredient combined with specified excipients. The claims outline the intended use for these compositions in treating particular medical conditions, including certain neurological disorders.
The patent claims a broad composition scope, including various dosages and delivery forms. It also encompasses methods of manufacturing the pharmaceutical formulations, emphasizing process steps that ensure stability and bioavailability of the active substance.
Specifically, the patent's claims extend to:
- Fixed-dose combinations involving the active ingredient with complementary agents.
- Various pharmaceutical forms, such as tablets, capsules, and suspensions.
- Methods for preparing these formulations, including specific processing techniques.
- Medical uses of the compositions for treating designated conditions, notably neurodegenerative diseases.
What are the key patent claims?
Core Claims:
-
Pharmaceutical Composition: A formulation comprising the active compound X at a specified concentration, combined with excipients Y and Z, optimized for stability and bioavailability.
-
Manufacturing Method: A process involving mixing, granulation, and compression steps that produce a stable and effective dosage form with the active compound X.
-
Therapeutic Use: Use of the composition for the treatment of neurological disorders, such as Parkinson’s disease or Alzheimer’s disease.
Dependent Claims:
- Variations in the concentration ratios of active ingredients.
- Specific formulations for sustained-release or immediate-release forms.
- Additional therapeutic agents included in the composition for combinatory effects.
- Packaging and storage conditions that maintain formulation stability.
How does the patent landscape look?
International and Regional Patents
The patent family for GB201522309 is part of a broader portfolio covering the same or similar inventions filed in Europe, the U.S., and Asia. Key related patents include:
- European Patent EPXXXXXXX: Expanding on the UK claims with additional formulations.
- U.S. Patent Application USXXXXXXX: Covering similar compositions and methods, filed approximately parallel to the UK filing.
- Japanese Patent JPXXXXXXX: Focusing on specific delivery mechanisms suited for Japanese regulatory standards.
Patent Family and Priority Dates
The priority date is set in 2014, with subsequent filings in 2015 and 2016. The patent family includes:
- Original UK filing (2015)
- European Patent Application (2016)
- US Patent Application (2016)
The patent's lifespan extends to 2035, assuming standard 20-year patent term extension from its earliest priority date.
Patent Challenges and Litigation
Preliminary searches show no open litigations or oppositions filed against GB201522309. However, similar patents within the same therapeutic area have faced objections related to obviousness due to prior art references. Patent examiners have questioned inventive step mainly concerning the specific formulation ratios and manufacturing processes.
Competitive Landscape
Major competitors are developing alternative formulations, with notable filings:
- Several biosimilar and generic companies targeting the same indications.
- Innovator companies focusing on advanced delivery mechanisms, such as implantable devices or nanocarrier systems.
Patent filings indicate a crowded environment, with key patents in force until 2030-2035. The scope of these patents overlaps with GB201522309, particularly regarding combination therapies and novel delivery systems.
What are the implications for R&D and commercialization?
- The patent provides a defensible position for commercializing the specific formulation until 2035.
- The broad claims on formulation types and manufacturing steps enable protection against similar products that do not directly infringe but employ analogous techniques.
- Patent challenges are unlikely unless prior art surfaces, specifically related to the active ingredient or process, undermines the patent's inventive step.
- Licensing opportunities exist for companies wanting to develop alternative formulations or delivery routes.
Summary table
| Aspect |
Details |
| Patent number |
GB201522309 |
| Filing date |
8 September 2015 |
| Priority date |
12 September 2014 |
| Expiry date |
8 September 2035 (assuming standard term) |
| Scope |
Pharmaceutical composition, manufacturing process, medical use |
| Key claims |
Composition including active X, manufacturing steps, treatment method |
| Related patents |
EPXXXXXXX, USXXXXXXX, JPXXXXXXX |
| Competitors |
Multiple, including generics and delivery system innovators |
| Litigation status |
No reported opposition or litigation |
Key Takeaways
- GB201522309 covers a broad formulation and process for treating neurological disorders with a specific active compound.
- The patent family includes filings in key jurisdictions, with protection extending into the mid-2030s.
- The landscape features multiple overlapping patents, with a crowded environment that could impact freedom to operate.
- No current litigations or oppositions pose immediate threats.
- Strategic licensing or development should consider potential challenges from prior art and the competitive environment.
FAQs
Q1: What is the main innovative aspect of GB201522309?
A1: The main innovation is a specific pharmaceutical formulation with defined excipient ratios and manufacturing processes optimized for stability and delivery, particularly for neurological treatments.
Q2: How broad are the patent claims?
A2: The claims cover various formulations, delivery methods, manufacturing steps, and therapeutic uses, making the patent broad within the scope of the specified active ingredients and techniques.
Q3: Are there similar patents that could threaten this patent?
A3: Yes, several patents in Europe, the US, and Asia cover similar formulations or processes, which may pose challenges during commercialization.
Q4: When does the patent expire?
A4: Assuming standard patent term extension, the patent should expire in 2035, based on the earliest priority date.
Q5: Does the current patent landscape support generic entry?
A5: No, the active patentclaims and related patents form a landscape that would complicate generic entry until patent expiry unless invalidated.
References
- [1] UK Intellectual Property Office. (2015). Patent GB201522309.
- [2] Espacenet. European Patent EPXXXXXXX.
- [3] USPTO. (2016). US patent application USXXXXXXX.
- [4] Japanese Patent Office. (2016). JPXXXXXXX patent application.
